Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Crucell, a biopharmaceutical company, has announced that supranational organizations awarded Crucell new contracts of $140 million for supplies of Quinvaxem and Hepavax-Gene for the period 2008 - 2009, bringing the total for the period 2007 - 2009 to $0.5 billion.
Subscribe to our email newsletter
These contracts are in addition to the December 1, 2006 announcement for the award of over $230 million for Crucell’s Quinvaxem and Hepavax-Gene vaccines, and the new contracts communicated on May 13, 2008 of $130 million for supplies of Quinvaxem in 2008 and 2009.
Ronald Brus, CEO of Crucell, said: “We are very excited to have received additional Quinvaxem contracts bringing the total value of the contracts awarded to date to $0.5 billion. These awards further confirm the superior quality of our pentavalent vaccine and the continued growth we expect from Quinvaxem.”